FindTrial
Sign In

REM-422

DRUG2 trials

Sponsors

Remix Therapeutics

Conditions

Acute Myeloid LeukemiaAcute Myeloid Leukemia RefractoryAdenoid Cystic CarcinomaHigher Risk Myelodysplastic SyndromesMetastatic Adenoid Cystic CarcinomaMyelodysplastic SyndromesRecurrent Adenoid Cystic Carcinoma

Phase 1

Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma
RecruitingNCT06118086
Remix TherapeuticsAdenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma
Start: 2023-12-20End: 2027-09-30Target: 125Updated: 2026-06-24
Study of REM-422 in Patients With AML or Higher Risk MDS
RecruitingNCT06297941
Remix TherapeuticsAcute Myeloid Leukemia, Acute Myeloid Leukemia Refractory, Higher Risk Myelodysplastic Syndromes +1
Start: 2024-04-26End: 2027-06-15Target: 100Updated: 2025-04-23

Related Papers

Clinical activity of REM-422, a MYB mRNA degrader, in recurrent/metastatic adenoid cystic carcinoma: Final results from the phase 1/2 dose-escalation cohort.
Journal of Clinical Oncology2026-05-27
Abstract 4030: Targeting MYB with REM-422 for the treatment of pediatric T-cell acute lymphoblastic leukemia - A report from the Pediatric Preclinical Testing Consortium (PIVOT)
Cancer Research2026-04-03
Abstract 1658: REM-422, a first-in-class mRNA degrader of the MYB oncogene, demonstrates anti-tumor activity in xenograft models of adenoid cystic carcinoma and acute myeloid leukemia
Cancer Research2025-04-21
REM-422, a Small Molecule MYB mRNA Degrader, Demonstrates Anti-Leukemic Activity As Monotherapy and in Combination with Standards of Care in Preclinical Models of AML
Blood2024-11-052 citations